Literature DB >> 78976

Serum-CSF protein gradients, the blood-GSF barrier and the local immune response.

G Schliep, K Felgenhauer.   

Abstract

For the majority of proteins there is a steady state equilbrium between the serum and the CSF compartment which depends upon the hydrodynamic radii of the passively transferred molecules. For clinical purposes the serum-CSF concentration ratios of albumin (Aalb) and alpha2-macroglobulin (Qalpha2 M) have proven to be a reliable barrier parameter, which is more sensitive than the total protein level in certain diseases, e.g. disk protrusions, degenerative processes and metabolic disorders. The immunoglobulins G and A cope with the passive transfer mechanism in both normal conditions and all degrees of pure barrier impairments but deviate in cases with local immunoglobulin production. The method described produces a quantitative differentiation between the locally synthesized and the serum-derived immunoglobulin fractions. A humoral immune response within the central nervous system was found in certain stages of acute infectious diseases and with chronic inflammatory processes such as subacute sclerosing panencephalitis, neurolues and multiple sclerosis.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 78976     DOI: 10.1007/BF02402169

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  37 in total

1.  A paraprotein IgA1 occurring in serum, urine, and cerebrospinal fluid (CSF): immunochemical and idiotypic evidence of synthesis in situ by the central nervous system (CNS).

Authors:  F Bollengier; A Mahler; A Gillard; E Wijffels
Journal:  J Clin Immunol       Date:  1986-07       Impact factor: 8.317

2.  Intrathecal IgG synthesis in multiple sclerosis and other neurological diseases: a comparative evaluation by IgG-index and isoelectric focusing.

Authors:  M Poloni; B Rocchelli; R Scelsi; P Pinelli
Journal:  J Neurol       Date:  1979-10       Impact factor: 4.849

3.  Isoelectric focusing and quantitative estimation of cerebrospinal fluid and serum IgG in idiopathic polyneuropathy.

Authors:  P Livrea; G B Zimatore; I L Simone; M Trojano; V Lepore; V Ferrara; F A Lupo; D Pedone
Journal:  J Neurol       Date:  1980       Impact factor: 4.849

4.  Isoelectric focusing of cerebrospinal fluid proteins in ischemic cerebrovascular disease.

Authors:  G Gudmundsson; K G Kjellin; K L Mettinger; A Sidén; C E Söderström
Journal:  J Neurol       Date:  1980       Impact factor: 4.849

5.  The discrimination between different blood-CSF barrier dysfunctions and inflammatory reactions of the CNS by a recent evaluation graph for the protein profile of cerebrospinal fluid.

Authors:  H Reiber
Journal:  J Neurol       Date:  1980       Impact factor: 4.849

6.  Intrathecal IgG synthesis in multiple sclerosis: comparison between isoelectric focusing and quantitative estimation of cerebrospinal fluid IgG.

Authors:  P Livrea; M Trojano; I L Simone; G B Zimatore; G Lamontanara; R Leante
Journal:  J Neurol       Date:  1981       Impact factor: 4.849

7.  Lumbar myelography with iopamidol: a methodological approach to the investigation of side effects.

Authors:  L Provinciali; M Signorino; A R Giovagnoli; M Baroni; F Angeleri; U Salvolini; U Pasquini; M Porta; A Judice; R Cerutti
Journal:  Neuroradiology       Date:  1988       Impact factor: 2.804

8.  Detection of immunoglobulin M in cerebrospinal fluid from syphilis patients by enzyme-linked immunosorbent assay.

Authors:  J B Lee; C E Farshy; E F Hunter; E A Hambie; G H Wobig; S A Larsen
Journal:  J Clin Microbiol       Date:  1986-11       Impact factor: 5.948

9.  Intramuscular nerves in motor neurone disease. A quantitative ultrastructural study.

Authors:  C P Case; M Jelaca
Journal:  Acta Neuropathol       Date:  1988       Impact factor: 17.088

10.  Blood-CSF barrier permeability and central nervous system immunoglobulin G in schizophrenia.

Authors:  D G Kirch; R C Alexander; R L Suddath; N M Papadopoulos; C A Kaufmann; D G Daniel; R J Wyatt
Journal:  J Neural Transm Gen Sect       Date:  1992
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.